NYSE:CHEChemed Stock Price, Forecast & News

Chemed's stock was trading at $414.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CHE stock has increased by 21.3% and is now trading at $502.39.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chemed.

Chemed is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Chemed.

Chemed Co. (NYSE:CHE) posted its quarterly earnings data on Wednesday, July, 29th. The company reported $4.41 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $3.75 by $0.66. The company had revenue of $502.20 million for the quarter, compared to analysts' expectations of $522.90 million. Chemed had a return on equity of 36.71% and a net margin of 12.99%. The business's revenue was up 6.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.36 earnings per share.
View Chemed's earnings history.

Chemed declared a quarterly dividend on Tuesday, May 19th. Stockholders of record on Thursday, May 28th will be given a dividend of $0.32 per share on Wednesday, June 17th. This represents a $1.28 annualized dividend and a dividend yield of 0.25%. The ex-dividend date of this dividend is Wednesday, May 27th.
View Chemed's dividend history.

Chemed updated its FY20 earnings guidance on Wednesday, July, 29th. The company provided earnings per share guidance of $16.20-16.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.13.

4 analysts have issued 12-month target prices for Chemed's stock. Their forecasts range from $490.00 to $535.00. On average, they expect Chemed's share price to reach $515.00 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price.
View analysts' price targets for Chemed.

Media stories about CHE stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chemed earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.
View the latest news about Chemed.

Chemed saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 177,700 shares, a drop of 24.8% from the June 30th total of 236,200 shares. Based on an average daily volume of 109,700 shares, the short-interest ratio is presently 1.6 days. Currently, 1.2% of the company's stock are short sold.
View Chemed's Current Options Chain.

Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Altria Group (MO), Target (TGT), Verizon Communications (VZ), AbbVie (ABBV), Boeing (BA), CVS Health (CVS), Chevron (CVX) and Johnson & Johnson (JNJ).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by many different institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (2.12%), Copeland Capital Management LLC (0.67%), First Trust Advisors LP (0.51%), Boston Trust Walden Corp (0.47%), Trinity Street Asset Management LLP (0.36%) and Envestnet Asset Management Inc. (0.30%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs.
View institutional ownership trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Riverbridge Partners LLC, Fort Washington Investment Advisors Inc. OH, First Trust Advisors LP, Raymond James Financial Services Advisors Inc., Robeco Institutional Asset Management B.V., NN Investment Partners Holdings N.V., and First Quadrant L P CA. Company insiders that have sold Chemed company stock in the last year include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, Spencer S Lee, and Walter L Krebs.
View insider buying and selling activity for Chemed.

CHE stock was purchased by a variety of institutional investors in the last quarter, including Trinity Street Asset Management LLP, Raymond James & Associates, Contravisory Investment Management Inc., Envestnet Asset Management Inc., UBS Group AG, Vident Investment Advisory LLC, Duality Advisers LP, and Empowered Funds LLC.
View insider buying and selling activity for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $502.39.

Chemed has a market capitalization of $7.97 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 16,641 workers across the globe.

The official website for Chemed is www.chemed.com.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.